Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Cardiolipin (CL) is a phospholipid required for proper mitochondrial function. Tafazzin remodels CL to create highly unsaturated fatty acid chains. However, when TAFAZZIN is mutated, CL remodeling is impeded, leading to mitochondrial dysfunction and the disease Barth syndrome. Patients with Barth syndrome often have severe exercise intolerance, which negatively impacts their overall quality of life. Boosting NAD+ levels can improve symptoms of other mitochondrial diseases, but its effect in the context of Barth syndrome has not been examined. We demonstrate, for the first time, that nicotinamide riboside can rescue exercise tolerance and mitochondrial respiration in a Drosophila Tafazzin mutant and that the beneficial effects are dependent on sir2 and spargel. Overexpressing spargel increased the total abundance of CL in mutants. In addition, muscles and neurons were identified as key targets for future therapies because sir2 or spargel overexpression in either of these tissues is sufficient to restore the exercise capacity of Drosophila Tafazzin mutants.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9558626 | PMC |
| http://dx.doi.org/10.1242/dmm.049279 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microbial diversity and composition in the gut microbiome of patients during systemic inflammatory response syndrome: can we use gut bacteria as potential biomarkers to characterize sepsis?
Front Cell Infect Microbiol
September 2025
Bacterial Resistance Research Laboratory (LABRESIS), Hospital de clínicas de Porto Alegre (HCPA), Experimental Research Center, Porto Alegre, Brazil.
Background: Critically ill patients, including those with systemic inflammatory response syndrome (SIRS) and sepsis, frequently exhibit gut microbiota disruption due to physiological stress and broad-spectrum antimicrobial therapy (AT). Although antibiotics are essential for controlling infection, they can destabilize the gut microbiota and may contribute to poorer clinical outcomes. The characterization of the gut microbiota of these patients may inform microbiota-based interventions to mitigate antibiotic-induced dysbiosis.
View Article and Find Full Text PDFBackground And Objectives: Thymidine kinase 2 deficiency (TK2d) is an ultra-rare, progressive, and life-threatening mitochondrial myopathy caused by pathogenic variants of the thymidine kinase 2 gene. Patients often lose the ability to walk, eat, and breathe independently. There are no approved therapies; however, preclinical studies of pyrimidine nucleos(t)ide therapy have shown promising results.
View Article and Find Full Text PDFGenetic suppression features ABHD18 as a Barth syndrome therapeutic target.
Nature
September 2025
Program in Genetics and Genome Biology, The Hospital for Sick Children, Toronto, Ontario, Canada.
Cardiolipin (CL) is the signature phospholipid of the inner mitochondrial membrane, where it stabilizes electron transport chain protein complexes. The final step in CL biosynthesis relates to its remodelling: the exchange of nascent acyl chains with longer, unsaturated chains. However, the enzyme responsible for cleaving nascent CL (nCL) has remained elusive.
View Article and Find Full Text PDFA novel gene variant c.525_533del causing Barth syndrome and leading to heart transplantation: a case report.
Front Pediatr
August 2025
Department of Cardiac, Vascular and Endovascular Surgery and Transplantology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Silesian Center for Heart Diseases in Zabrze, Zabrze, Poland.
Introduction: Barth syndrome (BTHS) is an ultra-rare genetic disease caused by a mutation in the gene, located on the X chromosome. This gene codes for the protein tafazzin, which is involved in the metabolism of the mitochondrial phospholipid - cardiolipin. Symptoms of this genetic defect include dilated cardiomyopathy (DCM), skeletal myopathy, neutropenia, growth retardation, reduced cholesterol levels, increased serum lactic acid levels, and hypoglycemia in the neonatal period.
View Article and Find Full Text PDFElamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.
Mol Genet Metab
August 2025
Department of Medical Genetics and Genomics, Icahn School of Medicine at Mount Sinai, 1428 Madison Ave, Atran Building, 1st Floor, New York, NY 10029, USA. Electronic address:
Barth syndrome is an exceedingly rare and potentially fatal X-linked mitochondrial disease arising from pathogenic variants in TAFAZZIN (TAZ), leading to defects in mature cardiolipin synthesis and its integration into the mitochondrial inner mitochondrial membrane. Clinical features that may be severe include cardiomyopathy, cyclic neutropenia, skeletal myopathy, and growth delay. Currently, no FDA-approved therapies exist.
View Article and Find Full Text PDF